A practical reference on regulatory status: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-06-04. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
In order to better assess radiation protection, the number of X-ray examinations, including the dose, has been recorded annually in Germany since 2007. However, the Federal Statistical Office does not have complete data for conventional X-ray examinations. In 2014, the total number of X-ray examinations in Germany was estimated to be about 135 million, of which about 55 million were dental X-ray examinations. The average effective dose from x-ray examinations per inhabitant in Germany in 2014 was about 1.55 mSv (about 1.7 x-ray examinations per inhabitant per year). The proportion of dental X-rays is 41%, but accounts for only 0.4% of the collective effective dose. In Germany, Section 28 of the X-ray Ordinance (RöV) has required since 2002 that the attending physician must have an X-ray pass available for X-ray examinations and offer it to the patient. The pass contains information about the patient's X-rays to avoid unnecessary examinations and to allow comparison with previous images. With the entry into force of the new Radiation Protection Ordinance on December 31, 2018, this obligation no longer applies. In Austria and Switzerland, x-ray passports have so far been available voluntarily. In principle, there must always be both a justifiable indication for the use of X-rays and the informed consent of the patient. In the context of medical treatment, informed consent refers to the patient's agreement to all types of interventions and other medical measures. § 630d Act of (in German)
=== Author === While known within the fandom for his spoken storytelling, Conway is also the author of several short stories published in various works by Sofawolf Press. In May 1998, Conway was invited to write a story based on his interest in birds of prey, particularly the red-tailed hawk. The result was "Tweaked in the Head", published December 1999 in Flights of Fantasy. He next contributed to the first issue of HistoriMorphs, a fanzine mixing historical fiction with interaction between humans and anthropomorphic animals. "The Secret of Wollknäul" took place in Nazi Germany at the end of World War II, and was published in June 2001. He went on to write "The Good Bird of Nanking" and "It Takes A Fox" for subsequent issues of the series. For Anthrolations #5—a magazine of dramatic fiction—Conway submitted "Six", a previously-written work "based on a true story" involving wildlife rehabilitation from his days as a Red Cross volunteer. The story, illustrated by Synnabar, was nominated for "Best Anthropomorphic Short Story" in the 2002 Ursa Major Awards. Also nominated that year was Breaking the Ice: Stories from New Tibet, a collection set in and around a subarctic mining colony; Conway's contribution, "Dead End", features a bartending vulture who provides an introduction to the harsh, dystopic world.
=== Synthesis and release === Oxcytocin is linked to the process of childbirth and milk ejection reflex. Oxytocin is produced in the brain and several reproductive tissues during pregnancy, while the receptors are produced in reproductive tissues. During human parturition, the quantifiable level of blood plasma oxytocin rises: it becomes twice as much during the initial phase of dilation and continues to increase until the second stage of labor. Oxytocin furthermore induces uterine contractions in mothers following childbirth which helps in the prevention of bleeding.
Sources: en.wikipedia.org
== See also == Metamaterials Handbook Metamaterials: Physics and Engineering Explorations Metasurface Artificial dielectrics—macroscopic analogues of naturally occurring dielectrics that came into use with the radar microwave technologies developed between the 1940s and 1970s. METATOY (Metamaterial for rays)—composed of super-wavelength structures, such as small arrays of prisms and lenses and can operate over a broad band of frequencies Magnonics
=== 2 February === The JDF claimed to have repelled an RSF attack on El Fasher, killing 140 fighters and mercenaries, destroying 43 vehicles and capturing 12 more. The JDF also said that RSF fighters were appearing more on foot and on camels and horses, and also appeared to be under the influence of drugs. The SAF retook Wad Rawah and al-Nabati in Gezira State. Renewed fighting and airstrikes in Darfur left at least 248 people dead or wounded.
=== Policy and advocacy === Laposata served on the Institute of Medicine Committee on Diagnostic Error in Health Care. The committee produced the 2015 report Improving Diagnosis in Health Care.[5] In August 2024 he served the Association for Molecular Pathology as a plaintiff in a lawsuit challenging the FDA's final rule on regulating laboratory developed tests.[2][4] In 2025 a federal district court in Texas vacated the rule.[4] That November, the Association for Molecular Pathology gave him its Champion for Innovation Award for his role in the case.[2]
== Adverse effects == Common adverse effects are constipation and nausea, but rates of discontinuation due to constipation were low for both eluxadoline and placebo. Rare adverse effects: fatigue, bronchitis, viral gastroenteritis. Rare serious adverse effects include pancreatitis with a general incidence of 0.3%: higher incidence with 100 mg dose (0.3%) than with 75 mg dose (0.2%). The risk is even greater in those who do not have a gallbladder and the medication is not recommended in this group. In March 2017, the U.S. Food and Drug Administration issued a safety alert for eluxadoline concerning an increased risk of serious pancreatitis in patients without a gallbladder. An FDA review found that in such patients, spasm of the sphincter of Oddi may lead to severe pancreatitis. The FDA reported that in some cases symptoms have occurred with just one or two doses at the recommended dosage for patients without a gallbladder (75 mg). Of two deaths associated with eluxadoline reported up to February 2017, both occurred in patients without a gallbladder.
Sources: en.wikipedia.org
== Partnerships == Pilot uses the lure of celebrities in their marketing, including players from the NRL team, the Cronulla Sharks, for which Pilot is a named sponsor. Mixed martial arts star Jack Della Maddalena and Australian swimmer James Magnussen have also been featured. In 2022, Pilot donated AUD $120,000 to the free phone counselling service, This is a Conversation Starter (TIACS).
The book presented her observations from more than 300 experiments over the span of five years, during which she attempted to discover factors necessary for the preservation of beef, eggs, and other foods. Her work was recommended for royal privilege by fellow chemist Pierre-Joseph Macquer. c. 1775: French explorer, herbalist and botanist Jeanne Baret becomes the first woman to circumnavigate the globe. c. 1775: French chemist, scientific artist and translator, Marie-Anne Paulze Lavoisier began working with her husband chemist Antoine Lavoisier. She was instrumental in the 1789 publication of her husband’s groundbreaking Elementary Treatise on Chemistry, which presented a unified view of chemistry as a field, as she drew diagrams of all the equipment used, and kept strict records that lent validity to the findings. She also translated and critiqued Richard Kirwan's 'Essay on Phlogiston and the Constitution of Acids' which led to the discovery of oxygen gas. 1776: At the University of Bologna, Italian physicist Laura Bassi became the first woman appointed as chair of physics at a university. 1776: German astronomer Christine Kirch received a respectable salary of 400 Thaler for calendar-making. See also her sister Margaretha Kirch 1782–1791: French chemist and mineralogist Claudine Picardet translated more than 800 pages of Swedish, German, English and Italian scientific papers into French, enabling French scientists to better discuss and utilize international research in chemistry, mineralogy and astronomy. c.
=== EC 1.99.2 Oxygenases (now covered by EC 1.13) === EC 1.99.2.1: deleted, now EC 1.13.11.12, lipoxygenase EC 1.99.2.2: deleted, now EC 1.13.11.1, catechol 1,2-dioxygenase EC 1.99.2.3: deleted, now EC 1.13.11.3, protocatechuate 3,4-dioxygenase EC 1.99.2.4: deleted, now EC 1.13.11.4, gentisate 1,2-dioxygenase EC 1.99.2.5: deleted, now EC 1.13.11.5, homogentisate 1,2-dioxygenase EC 1.99.2.6: deleted, now EC 1.13.99.1, inositol oxygenase
Nerve injury classification assists in prognosis and determination of treatment strategy for nerve injuries. The classification was described by Seddon in 1943 and by Sunderland in 1951. In the lowest degree of nerve injury the nerve remains intact, but signaling ability is damaged, termed neurapraxia. In the second degree the axon is damaged, but the surrounding connecting tissue remains intact – axonotmesis. The last degree, in which both the axon and connective tissue are damaged, is called neurotmesis.
=== Formulations === Available dosage forms include liquids, syrups, drops, elixirs, effervescent tablets, and powders for mixing with water, capsules, tablets including extended-release formulations, suppositories, compounding powder, and injections.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.